Skip to content

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06839391
Enrollment
120
Registered
2025-02-21
Start date
2025-03-31
Completion date
2026-04-30
Last updated
2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tab Block Qaulity

Keywords

hyaluronidase-bupivacaine-TAB block

Brief summary

evaluate the efficacy of hyaluronidase in different doses as an adjuvant to bupivacaine in ultrasound-guided TAB block during CS

Detailed description

Hyaluronidase acts by catalyzing the hydrolysis of hyaluronan, decreased its viscosity, and enchasing the tissue permeability. So, this makes it a suitable additive for other drugs to speed up their distribution and delivery especially in ophthalmic surgery. Several studies showed that multiple injection techniques of TAB block were more successful with a faster onset of anesthesia and higher success rates, with a change in the incidence of complications. This double-blinded randomized prospective study was conducted to evaluate the efficacy of hyaluronidase in different doses as an adjuvant to bupivacaine in ultrasound-guided TAB block during CS . The primary outcome of this study was the duration of sensory block, while secondary outcomes included the onset of sensory block, success rate, total doses of intraoperative rescue analgesia, number of patients needed for postoperative rescue analgesia, and complications.

Interventions

Effect of hyaluronidases in different doses added to bupivacaine on quality of ultrasound-guided TAB block during CS ,

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* pregnant 20-45 y medical free

Exclusion criteria

* • Hepatic. * Renal. * Diabetic. * Hypertensive. * Cardiovascular dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
visual analogue scale2-6-10-16-24 hours postoperativelypostoperatively pain assesment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026